Valuation SCYNEXIS, Inc.

Stocks

Market Closed - Nasdaq 01:30:00 24/10/2026 am IST			5-day change	1st Jan Change
3.785 ^USD	-0.66%		+3.13%	-25.19%

22/10	SCYNEXIS, Inc. Completes Phase 1 Study Of Intravenous SCY-247	CI
06/10	SCYNEXIS, Inc. Announces Completion Of Phase 1 Study Of SCY-770 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	174	50.94	82.97	45.92	26.54	37.66	-	-
Change	-	-70.72%	62.87%	-44.66%	-42.2%	41.9%	-	-
Enterprise Value (EV)	174	50.94	82.97	45.92	26.54	37.66	37.66	37.66
Change	-	-70.72%	62.87%	-44.66%	-42.2%	41.9%	0%	0%
P/E	-4.88x	-1.06x	1.6x	-2.75x	-3.72x	-1.3x	-1.63x	-2.28x
PBR	-	-	-	-	-	-	-	-
PEG	-	-0.1x	-0x	0x	0.1x	-0x	0.1x	0.1x
Capitalization / Revenue	13.2x	10x	0.59x	12.3x	1.29x	60.8x	5.64x	2.67x
EV / Revenue	0x	0x	0x	0x	0x	60.8x	5.64x	2.67x
EV / EBITDA	-	-	-	-	-	-	-	-
EV / EBIT	-0x	-0x	0x	-0x	-0x	-0.93x	-1.52x	-1.64x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-10	-11.76	11.12	-3.52	-1.36	-2.91	-2.315	-1.66
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	13.16	5.091	140.1	3.746	20.6	0.6195	6.677	14.08
EBITDA	-	-85.15	-	-	-	-	-	-
EBIT ¹	-60.84	-85.76	72.67	-37.12	-16.07	-40.32	-24.83	-22.96
Net income ¹	-32.87	-62.81	67.04	-21.29	-8.609	-30.55	-32.43	-22.46
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	48.800	12.480	17.840	9.680	5.059	3.785	3.785	3.785
Nbr of stocks (in thousands)	3,565	4,082	4,651	4,744	5,246	9,950	-	-
Announcement Date	29/03/22	31/03/23	28/03/24	12/03/25	04/03/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
SCYNEXIS, INC.	-1.3x	-	-	-	3.77Cr
ELI LILLY AND COMPANY	37.06x	13.1x	27.8x	0.54%	1,13500Cr
JOHNSON & JOHNSON	38.61x	6.49x	18.27x	2.02%	64TCr
ABBVIE INC.	36.46x	8.38x	17.29x	2.41%	50TCr
ROCHE HOLDING AG	20.87x	5.11x	12.73x	2.56%	38TCr
MERCK & CO., INC.	105.89x	5.92x	25.41x	2.34%	36TCr
NOVARTIS AG	21.76x	5.68x	13.94x	2.81%	29TCr
ASTRAZENECA PLC	22.43x	4.53x	12.94x	1.95%	27TCr
AMGEN INC.	27.87x	7.16x	12.81x	2.3%	24TCr
GILEAD SCIENCES, INC.	-45.48x	6.98x	27.06x	2.11%	19TCr
Average	26.42x	7.04x	18.69x	2.12%	40.04TCr
Weighted average by Cap.	35.23x	8.29x	20.39x	1.8%